Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

Bone Marrow Transplantation

Volumn 29, Issue 4, 2002, Pages 303-312

  Rapoport, A P ^a   Meisenberg, B ^a   Sarkodee Adoo, C ^a   Fassas, A ^b   Frankel, S R ^a   Mookerjee, B ^a   Takebe, N ^a   Fenton, R ^a   Heyman, M ^a   Badros, A ^a   Kennedy, A ^a   Jacobs, M ^a   Hudes, R ^a   Ruehle, K ^a   Smith, R ^a   Kight, L ^a   Chambers, S ^a   MacFadden, M ^a   Cottler Fox, M ^b   Chen, T ^a   Phillips, G ^a   Tricot, G ^b   more..

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

Author keywords

Autotransplantation; Consolidation chemotherapy; Hodgkin's disease; Lymphoma; Radiotherapy; Rituxan

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FAMCICLOVIR; FLUCONAZOLE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; PACLITAXEL; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; KAPLAN MEIER METHOD; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SEPSIS; STEM CELL MOBILIZATION; T CELL LYMPHOMA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS;

EID: 0036124560     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703363     Document Type: Article

References (49)

1. Autotransplantation in lymphoma: Better therapy for healthier patients?
2. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy. The low probability for cure
3. Prognostic factors for treatment outcome in autotransplantation of intermediate grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide
4. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma
5. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma
6. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry
7. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma
8. High-dose chemotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: An intention-to-treat analysis
9. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens - A Southwest Oncology Group trial
10. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma
11. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma
12. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors
13. Autotransplantation for relapsed or refractory Hodgkin's disease: Long-term follow-up and analysis of prognostic factors
14. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Transplantation
15. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: A phase North American Marrow Transplant Group
16. Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the autologous blood and marrow transplant registry
17. High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: Long-term outcome and prognostic factors
18. Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR)
19. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group
20. Expression of a multidrug resistant gene in human cancers
21. P-glycoprotein in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil
22. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas
23. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma
24. Clinical significance of bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study
25. An information-intensive approach to the molecular pharmacology of cancer
26. Comparison of the cellular pharmacokinetics and toxicity of 2′2′-difluoro-deoxycytidine and 1-β-D-arabinofuranosylcytosine
27. Evaluation of the anti-tumor activity of gemcitabine (2′2′-difluoro-2′-deoxycytidine)
28. Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias
29. Phase II study with gemcitabine in pretreated patients with Hodgkin's (HD) and non-Hodgkin's lymphomas (NHL): Results of a multicenter study
30. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: Application in bone marrow transplantation
31. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence antibodies
32. Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation
33. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies
34. Dexamethasone, cyclophosphamide, etoposide and Cis-platinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT)
35. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study
36. Antiapoptosis potential of bcl-2 oncogene by dephosphorylation
37. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas
38. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: Final report of a phase II trial
39. Activity of taxol and high-dose cytoxan with granulocyte colony-stimulating factor (G-CSF) in 54 patients with relapsed/refractory non-Hodgkin's lymphoma (NHL)
40. Nonparametric estimation from incomplete observation
41. Regression models and life tables
42. Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications
43. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma
44. Adoptive transfer of CD3/CD28 ex vivo costimulated T-cells in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) following high dose chemotherapy (HDC) with CD34-selected peripheral blood stem cell (PBSC) support
45. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
46. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
47. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
48. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial
49. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells